How intravenous drips of vitamins are becoming popular and why doctors flag them as unnecessary

A person associated with a wellness centre in Gurgaon says on condition of anonymity that the vitamin IV “therapy” is gaining traction and the footfall the centre is getting is increasing every month. “The number of people opting for IV vitamins has gone up by 30-40% over last year,” he says, adding, “We offer packages depending on what one wants. A screening is done by our in-house doctor and then a cocktail is decided.” Instead of popping multivitamin tablets, why do people opt for intravenous drips? “When vitamins are taken orally, the absorption rate is 20-50%. However, it is 90-100% when it is given intravenously,” the person says. It is sought by people in the metros, he adds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MbpW7Gf
via IFTTT

Read More

Drug sales get a monsoon twist in August

Liver herbal supplement Liv 52 emerged as one of India's top-selling herbal tonics in August, driven by increased cases of liver-related illnesses during the monsoon season. The Indian pharmaceutical market saw a 6.3% growth year-over-year, with gastrointestinal and anti-diabetic medications performing strongly in both sales value and volume.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EyuMvXq
via IFTTT

Read More

Ayushman Bharat enrollment for senior citizens to start in a week

Enrollment for senior citizens aged 70 and above under the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) will begin soon. Initially launching as a pilot program, eligible seniors can apply through the Ayushman mobile app or PMJAY portal. The scheme offers free health insurance coverage of up to Rs 5 lakh annually on a family basis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yDRJhuM
via IFTTT

Read More

Healthcare, manufacturing sector to benefit most from Fed rate cuts: Motilal Oswal

As the U.S. Federal Reserve's anticipated rate cut approaches, a report by Motilal Oswal suggests that the healthcare and manufacturing sectors are expected to benefit the most. Healthcare is projected to be the fastest-growing sector, while manufacturing may see technological advancements. Challenges remain for BFS, retail, and hi-tech industries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Rd8yeFZ
via IFTTT

Read More

Alkem joins $3 bn race for JB Chem as Torrent pauses talks

Alkem Laboratories, India's fifth-largest branded pharmaceutical company, is vying for JB Chemicals and Pharmaceuticals as KKR looks to sell. Torrent Pharmaceuticals has exited negotiations over valuation differences. If successful, this will be Alkem's largest acquisition, enhancing its presence in the chronic segment and potentially moving it to fourth place in the domestic formulations market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WFzC6X1
via IFTTT

Read More

Kiran Mazumdar-Shaw calls for innovation-driven value creation in India's biotech sector

Biocon Chairperson Kiran Mazumdar-Shaw urges increased investment in research and development to drive innovation and intellectual property culture. Speaking at Global Bio-India 2024, she highlights India's potential as a global bio-innovation hub, emphasizing its scientific talent and technological capabilities. She also underscores the importance of biotechnology in healthcare and agriculture.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sRV9xg0
via IFTTT

Read More

DNA Wellness to invest Rs 200 cr to set up over 100 cervical cancer screening labs

Ahmedabad-based DNA Wellness will invest Rs 200 crore to establish over 100 cervical cancer screening labs across India by 2027. The company has exclusive rights to conduct the DNA Ploidy Test, developed by the British Columbia Cancer Research Agency. The first CERViSure lab has been launched in Ahmedabad, with plans for more labs in Gujarat by October 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mSZtNxk
via IFTTT

Read More

Durex makes India condom push for women, rural consumers

Reckitt Benckiser, the world's largest condom maker, is shifting its focus in India to target women and rural consumers. With changing attitudes towards female pleasure and a rise in condom use among Indian women, Reckitt is reformulating products and launching new marketing campaigns. The company faces challenges with distribution, pricing, and conservative societal norms but sees significant growth potential in India's expanding market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2gnU5Zl
via IFTTT

Read More

DCGI suspends nod to Entod's new eye drops over unapproved 'claims'

India's drug regulator has suspended Entod Pharmaceuticals' permission to manufacture and sell PresVu Eye Drops. The company did not obtain clearance for its claim that the drops reduce dependency on reading glasses for presbyopia. Entod plans to challenge the suspension in court, asserting that their clinical trials demonstrated efficacy and safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dh4IsHS
via IFTTT

Read More

Bharat Biotech inks pact with Alopexx for anti-microbial vaccine

Bharat Biotech has partnered with Alopexx, Inc. to co-develop and commercialize the anti-microbial vaccine AV0328 in India and other low-income countries. The collaboration aims to address antimicrobial resistance through vaccination, with Alopexx receiving upfront and milestone payments, as well as royalties on future sales in licensed territories.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tMWp0zS
via IFTTT

Read More

Jaggery or sugar: Which sweetener is better for your health?

Jaggery is healthier due to its nutrient content, lower glycemic index, liver detox benefits, digestive aid, immune boost, and minimal processing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y3QicrD
via IFTTT

Read More

8 essential plants you should have for a mosquito-free home

Looking for natural ways to keep mosquitoes at bay? Incorporating mosquito-repelling plants into your garden or home can be both effective and aesthetically pleasing. Here are eight plants that not only enhance your outdoor space but also help keep pesky insects away.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/N7XljdL
via IFTTT

Read More

US animal health major Zoetis expands GCC in Hyderabad, to add 300 jobs by 2025

Zoetis, the world's largest producer of pet and livestock medicine, is expanding its global capability centre in Hyderabad. The centre will add around 300 technology jobs by next year and support the company's global operations using advanced technology tools. This expansion aims to leverage Hyderabad's tech talent pool and life-science ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qSGvzW4
via IFTTT

Read More

Plant for production of Penicillin G & Clavulanic acid to start soon: Department of Pharmaceuticals

The Department of Pharmaceuticals has announced that India will soon start producing Clavulanic Acid, a key ingredient in the antibiotic Augmentin. This move is part of the Production Linked Incentive scheme aimed at reducing dependency on foreign imports and boosting local manufacturing of essential bulk drugs like Penicillin G and Clavulanic Acid.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zKT5GCB
via IFTTT

Read More

Johnson & Johnson told to pay ₹35 lakh each as compensation to hip implant victims

The National Consumer Disputes Redressal Commission has ordered Johnson & Johnson to pay ₹35 lakh in compensation to each patient affected by a faulty hip implant. The commission also mandated an interest of 6% per annum on the compensation from the complaint filing date. The payment must be made within two months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TkCvjgN
via IFTTT

Read More

Fortis seeks CCI nod to buy 31.52% more in diagnostics subsidiary Agilus

Fortis Healthcare has sought approval from the Competition Commission of India to acquire an additional 31.52% stake in its diagnostics arm, Agilus, raising its shareholding to 89.2%. The deal, valued at ₹1,780 crore, involves buying stakes from private equity players. Additionally, Aquilo House Pte seeks approval to acquire a 26.47% stake in Aavas Financiers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d1TNWH4
via IFTTT

Read More

EQT to acquire ChrysCap-owned healthcare BPO GeBBS

Swedish Private Equity fund EQT has acquired GeBBS Healthcare Solutions from ChrysCapital for approximately $860-870 million. GeBBS, a provider of revenue cycle management services, has seen significant growth under ChrysCapital's ownership. The acquisition aligns with EQT's focus on healthcare technology and aims to further accelerate GeBBS' growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3FzQaBW
via IFTTT

Read More

Looking to lose weight? Try these 6 bedtime yoga poses!

These poses, done consistently, can aid in weight loss by reducing stress, improving digestion, and promoting better sleep.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d9Ytn05
via IFTTT

Read More

Building muscle mass: Why the growing lure of protein supplements is worrying health experts

The protein revolution is transforming diets across India, with many turning to supplements to meet their nutritional needs. This trend is driving a booming industry but also raising concerns about the indiscriminate use of protein powders. Experts advocate for balanced diets and caution against over-reliance on marketed products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VioM3mr
via IFTTT

Read More

7 bad habits to avoid after 40 for a healthier life

Here are seven bad habits to quit after 40 to improve health and well-being:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dRDKClo
via IFTTT

Read More

Wockhardt says acted as per laws, denies Congress' charges over affiliate rental payments to Sebi chief

Wockhardt has refuted allegations of conflict of interest and corruption made by the Congress party against SEBI chairperson Madhabi Puri Buch. The claims relate to rental payments by Carol Info Service, an affiliate of Wockhardt, which is involved in multiple cases with SEBI, including insider trading. Wockhardt termed the allegations as baseless and misleading.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rUGg3dR
via IFTTT

Read More

India takes tiny steps back from its China dependency

India is striving to reduce its dependency on China for pharmaceutical raw materials by promoting domestic production through a Production-Linked Incentive scheme. Companies like Kinvan and Aurobindo Pharma are stepping up to produce essential components locally, aiming for self-sufficiency in the pharma sector, especially highlighted during the Covid pandemic.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n1yklau
via IFTTT

Read More

Novo Nordisk not yet ready to bring in popular obesity, diabetes injectables

Novo Nordisk's launch of weight-loss and diabetes drugs Wegovy and Ozempic in India hinges on resolving supply issues. The company is scaling up production and may consider local fill-finish options. Currently, the injectable forms are not approved in India, leading to high demand in grey markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xHSkP0l
via IFTTT

Read More

Strides gets USFDA nod for Theophylline extended-release tablets

Strides Pharma Science Ltd announced that its subsidiary has received approval from the USFDA for its generic version of Theophylline extended-release tablets, used to manage chronic asthma and other respiratory conditions. The tablets, available in 300 mg and 450 mg doses, will be produced at their Bengaluru facility and have a market size of around USD 11.5 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dDlAq1O
via IFTTT

Read More

India starts making key API clavulanic acid

India has begun producing clavulanic acid, a key ingredient in the antibiotic Augmentin, reducing its reliance on China for APIs. Mumbai-based Kinvan is leading this initiative, with plans to scale up production to 300 metric tons by the end of the year. This move aligns with India's production-linked incentive scheme.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x8qYw7W
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic product

Alembic Pharmaceuticals has received approval from the USFDA to market Albendazole Tablets USP (200 mg), a generic drug for treating infections caused by worms. The tablets are equivalent to Impax Laboratories' Albenza and are used for conditions like parenchymal neurocysticercosis and cystic hydatid disease. Alembic Pharma shares rose 2.79% on Thursday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tl8GQaC
via IFTTT

Read More

Need to strike fine balance between making hospitals secure and accessible: AIIMS-Delhi director

Dr. M Srinivas, Director of AIIMS-Delhi, has highlighted the need for balancing hospital security and accessibility amid demands for a safer work environment following the RG Kar rape-murder case. He underlined the importance of improving infrastructure and working conditions for medical professionals while ensuring patient care remains a priority.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SGpDgnU
via IFTTT

Read More

Potential outbreak-causing dangerous viruses found in China’s fur animals

Scientists have discovered novel and potentially dangerous viruses in raccoon dogs, mink, and other fur-farmed animals in China. The study found 125 virus species, including 36 novel ones, with 39 posing a high risk of crossing the species barrier. This highlights the need for better virus surveillance in fur-animal farming.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aUwg9mO
via IFTTT

Read More

EQT set to acquire BPO GeBBS from ChrysCapital

Swedish private equity fund EQT is set to acquire Los Angeles-based healthcare BPO company GeBBS Healthcare Solutions for about $870 million. The deal, which outbid Hillhouse Investment, is expected to be signed soon. GeBBS, founded in 2005, employs 14,000 workers globally and competes with major firms like Wipro and IBM.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ncdX7e0
via IFTTT

Read More

Lactose intolerant? 6 top non-dairy calcium sources for healthy bones

Here are 6 non-dairy sources of calcium that are great for maintaining healthy bones:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BAuIFPY
via IFTTT

Read More

Natco Pharma acquires 40 million shares in eGenesis Inc

Natco Pharma's Canadian subsidiary has acquired 40 million shares in eGenesis Inc. for USD 8 million. eGenesis is a biotechnology company developing human-compatible organs for transplant through xenotransplantation. This investment aims to support eGenesis' pioneering work in kidney, liver, and heart transplants, potentially addressing the global transplant shortage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0X8Lkc5
via IFTTT

Read More

No link between mobile phones and brain cancer, WHO-backed study says

A World Health Organization-commissioned review has found no link between mobile phone use and an increased risk of brain cancer. The study, which analyzed data from 63 studies between 1994 and 2022, showed no rise in brain cancer cases despite the surge in wireless technology usage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ry2vViu
via IFTTT

Read More

Cipla's vice-chairman MK Hamied resigns citing age and health, his son Kamil to join the board

Cipla's vice-chairman MK Hamied has resigned from the board due to age and health concerns, effective October 29, 2024. His son Kamil Hamied will join as a non-executive director from November 1, 2024. Cipla also appointed Adil Zainulbhai and Abhijit Joshi as additional directors starting September 3, 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/h0PqOS9
via IFTTT

Read More

Cipla's MK Hamied resigns from the company due to health reasons

Cipla's Vice Chairman and Non-Executive Director, Mr. M K Hamied, has resigned from his position due to age and health reasons. His resignation will be effective from the close of business hours on October 29, 2024. In a letter to employees, Hamied expressed pride in his tenure and confidence in Cipla's future success.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bBGapOy
via IFTTT

Read More

Mankind: How Meerut brothers built India's 4th largest pharma firm

Mankind Pharma has announced a significant move by acquiring Bharat Serums and Vaccines Ltd for Rs 13,630 crore. The acquisition, partly funded by debt, aims to strengthen Mankind’s portfolio. The Juneja brothers are confident in their strategy despite market concerns about integration and cost.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nbZ3jD2
via IFTTT

Read More

Mankind Pharma eyes ₹9,000 cr via debt to stitch BSV deal

The average blended cost of the debt is likely to be around 8.50% with the firm seeking to borrow money over one- to-five years, said three people familiar with the plans. "Bankers have already approached large mutual funds to place the debt, which will range from one year and may go up to five years looking at the demand," said one of the persons.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kcw4QbH
via IFTTT

Read More

Alkem inks licensing pact with Takeda to introduce Vonoprazan in India

Alkem Laboratories has entered into a patent licensing agreement with Takeda Pharmaceutical to market Vonoprazan in India. This medication is used to treat conditions like reflux esophagitis and various ulcers. This licensing deal will enhance Alkem's offerings in the gastrointestinal segment, according to CEO Vikas Gupta. The company's shares dropped 1.66% on Monday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ulcrmtk
via IFTTT

Read More

How to control blood sugar naturally: 7 tips

Discover seven natural strategies to balance blood sugar levels, including increasing fiber intake, staying hydrated, exercising, and managing stress effectively.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f0gCyh7
via IFTTT

Read More

Biocon unit gets USFDA nod for generic drug

Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing. Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u6aRht3
via IFTTT

Read More

AI-powered device successfully treats blood clot in a 28-year-old

A 28-year-old man with acute pulmonary thromboembolism was successfully treated at Sir Gangaram Hospital using an AI-powered device designed to remove blood clots accurately. The device prevents severe blood loss by targeting only clots. This method avoids the risks associated with conventional treatments like internal bleeding and repeated interventions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/weUABvg
via IFTTT

Read More

PCOS on the rise in young women: Are you at risk?

PCOS is increasingly affecting young women. Discover the key risk factors, symptoms, and management strategies to protect your health and well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ya7CcSh
via IFTTT

Read More

Sooji breakfast recipes: 5 healthy and easy options to try

Here are five healthy breakfast ideas using sooji (semolina):

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BVgCYqa
via IFTTT

Read More

Zydus Lifesciences gets warning letter from USFDA for its Jarod injectable unit

Zydus Lifesciences received a warning letter from the USFDA regarding its injectables manufacturing facility at Jarod, following an inspection in April 2024. The letter cites violations of cGMP regulations. Zydus must respond within 15 days and take remedial action. The warning limits new product launches, impacting business growth in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ufi6SM5
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod to market Scopolamine transdermal system

Zydus Lifesciences Ltd has received USFDA approval to market its Scopolamine transdermal system, which helps prevent nausea and vomiting under various conditions, including after surgery and due to motion sickness. The product, with a dosage of 1 mg/3 days, will be manufactured in Ahmedabad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kSlFUcB
via IFTTT

Read More

7 protein-packed dinners for healthy weight loss

These 7 high-protein dinner recipes, including grilled chicken salad, baked salmon, and quinoa bowls, are designed to help with weight loss by providing satisfying, nutrient-rich meals that support your goals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wb5dFV0
via IFTTT

Read More

Monkeypox RT-PCR Test: A step-by-step guide for accurate results

Discover how to accurately use the Monkeypox RT-PCR test kit: from sample collection to handling and lab processing. Ensure reliable results with these essential steps.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cowmiuJ
via IFTTT

Read More

Listeria infection: Symptoms, source, and prevention

Over 50 hospitalized and 9 deaths reported in a major Listeria outbreak. Contaminated deli meats are linked to the outbreak. Learn about symptoms and safety tips.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7a5fupW
via IFTTT

Read More

Want to purify your blood? Try these 6 foods

Discover 6 natural foods that can help purify your blood, removing toxins and improving circulation. From beetroot to turmeric, these everyday ingredients support detoxification and enhance overall health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SuOZPnU
via IFTTT

Read More

Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan

Biocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson to launch Bmab 1200, a biosimilar to Stelara, in Europe, the UK, Canada, and Japan. This deal resolves patent disputes and secures future market entry, pending regulatory approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/31h8gKJ
via IFTTT

Read More

Indian pharma exporters feel pain on Bangladesh crisis

The political unrest and violence in Bangladesh are posing significant challenges for Indian pharmaceutical exporters, leading to stranded funds and concerns over financial stability. This situation threatens to impact medicine availability and healthcare services in Bangladesh. Despite the market's growth potential, many Indian companies are now hesitant to supply without advance payments, emphasising the importance of risk management in this unpredictable scenario.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VaBeDh5
via IFTTT

Read More

Hillhouse bids highest to buy healthcare BPO GeBBS from Chrys Cap for $870 mn

GeBBS Healthcare Solutions, a Los Angeles-based healthcare BPO firm, is nearing acquisition by Hillhouse Investment, which has offered about $870 million. The final decision is expected in two weeks as ChrysCapital holds another round of negotiations. The acquisition will potentially see industry veterans Gautam Barai and Gautam Narayan at the helm.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ac8Q2mK
via IFTTT

Read More

Sloth fever outbreak: Key facts on the deadly virus and should you be worried?

The Oropouche virus, also known as "sloth fever," is spreading in South America and the Caribbean. Transmitted by midges and mosquitoes, it causes symptoms similar to dengue and Zika, with no vaccine or specific treatment available.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y175rKt
via IFTTT

Read More

Fairfax, Bain look to buy Gujarat's API Company Farmson

Canadian billionaire Prem Watsa's Fairfax Group and Bain Capital are in competition for a buyout of Farmson Basic Drugs, a leading API maker in India valued at ₹4,000 crore. Founded in 1969, Farmson is a major paracetamol manufacturer with a revenue of ₹1,750 crore in FY24. The company's concentrated focus on paracetamol production is a strength, but limited R&D poses challenges for diversification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/euQimrX
via IFTTT

Read More

Bharat Biotech launches oral cholera vaccine Hillchol after positive phase 3 trial

Bharat Biotech unveiled Hillchol, a new single-strain oral cholera vaccine, developed with Hilleman Laboratories. Addressing the high global demand for cholera vaccines, the company can produce up to 200 million doses annually. Phase 3 trials validated its safety and effectiveness. The vaccine is administered orally to individuals over one year old.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H3g9cIF
via IFTTT

Read More

India develops indigenous Monkeypox RT-PCR testing kit, gets CDSCO approval

India has successfully developed its own indigenous RT-PCR testing kit to combat Monkeypox. The kit, created by Siemens Healthineers, has received manufacturing approval from the Central Drugs Standard Control Organisation (CDSCO).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jkEF31M
via IFTTT

Read More

More fixed-dose combo drugs may enter ban list

The Indian government recently banned 156 fixed-dose combination drugs, citing health risks. An expert committee found these combinations lacking therapeutic justification. More FDCs are under review and could face imminent bans as part of ongoing evaluations to ensure public safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZW1Qoh2
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic drug

Alembic Pharmaceuticals has been granted final approval from the USFDA for its generic Betamethasone Valerate Foam, intended to treat moderate-to-severe psoriasis of the scalp. This medication is equivalent to Luxiq Foam by Norvium Bioscience. Alembic’s shares ended 0.97% lower at Rs 1,089.90 on the BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NvMEqjc
via IFTTT

Read More

TB testing technology developed by ICMR's regional centre allows tests at Rs 35

ICMR has introduced a new CRISPR-based technology for detecting tuberculosis at a low cost. Capable of testing 1,500 samples in a short period, this system aims to address limitations of existing methods. ICMR plans to commercialise this technology, offering technical support and seeking partner organisations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vL0J2VM
via IFTTT

Read More

Pharma companies seek more time to implement revised norms on manufacturing practices

Schedule M of the Drugs and Cosmetics Rules, 1945 prescribes the good manufacturing practices (GMP) for pharmaceutical products, such as a prompt product recall system for products known or suspected to be defective. Pharma lobby groups have written to the health minister, seeking an extension of the December 2024 deadline to December 2026, citing lack of resources and challenges faced by the industry in implementing the revised norms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/V4A2PCw
via IFTTT

Read More

India aims to lead next industrial revolution with biomanufacturing policy: DBT

India introduced the BioE3 policy to tackle challenges related to food, energy, and climate. Approved by the Union Cabinet, the policy focuses on enhancing innovation in biomanufacturing, covering everything from medicines to bio-plastics. The initiative is expected to create job opportunities and promote sustainable development. The policy aligns with India's aim to become a developed nation by 2047, providing alternatives to traditional resources and addressing environmental concerns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bLraidZ
via IFTTT

Read More

Danfoss India confident of doubling sales by 2025, company president says

Danfoss India, a subsidiary of the Denmark-based Danfoss Group, is experiencing significant growth in the Indian market and aims to double its sales by 2025. The Indian market is the fastest-growing region for Danfoss, driven by increased opportunities in energy efficiency and electrification. The company reported a 10.6% EBITDA margin for the first half of the year, down from 12.4% last year, with overall sales of €5 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jn7PNtl
via IFTTT

Read More

USFDA pulls up Eugia for manufacturing lapses, data accuracy at Hyderabad plant

The US Food and Drug Administration (USFDA) has issued a warning letter to Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, citing significant manufacturing issues at its Telangana plant. The USFDA's inspection from January 22 to February 2, 2024, revealed problems including inaccurate production and process simulation data, falsified environmental monitoring records, and incomplete batch production and control records.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vt1BpDZ
via IFTTT

Read More

Revoke 18% GST on health and life insurance premium: TMC to Nirmala Sitharaman

TMC leader Derek O'Brien has urged Finance Minister Nirmala Sitharaman to remove the 18% GST on health and life insurance premiums at the upcoming GST Council meeting. He argues that the tax is a burden on the middle class and may discourage people from buying or renewing insurance. O'Brien cited a February 2024 report from the Standing Committee on Finance recommending a reduction in GST rates to make insurance more affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pxAW2q3
via IFTTT

Read More

Zydus Lifesciences acquires 50% stake in Sterling Biotech

Zydus Lifesciences entered a joint venture with Perfect Day by acquiring a 50% stake in Sterling Biotech. The collaboration aims to build a manufacturing facility for animal-free protein products, addressing global demand. This venture marks Zydus' entry into the biotech sector, focusing on health and nutrition solutions for lactose-intolerant consumers and those preferring animal-free options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KLn5ITj
via IFTTT

Read More

Zydus Lifesciences to acquire 50 pc stake in Sterling Biotech from Perfect Day

Zydus Lifesciences announced an agreement with Perfect Day Inc to acquire a 50 per cent stake in Sterling Biotech. The partnership aims to establish a manufacturing facility for animal-free protein production. This move signifies Zydus' expansion into specialized biotech products catering to health and nutrition markets, particularly for those preferring animal-free or lactose-intolerant options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mXOgoDy
via IFTTT

Read More

How to reduce belly fat without exercise

Losing belly fat without exercise is achievable through dietary adjustments, lifestyle changes, and mindful practices. Here are some effective strategies:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K2GfLaO
via IFTTT

Read More

Govt bans 156 fixed-dose combo drugs over risks

FDCs are medicines that combine two or more drugs into a single dosage. The union health and family welfare ministry on Thursday issued a gazette notification, prohibiting manufacture, sale and distribution of these medicines based on the recommendation of an expert panel that evaluated 324 FDCs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/98mzx2L
via IFTTT

Read More

B'desh upheaval takes a toll on medical tourism in India

The number of Bangladeshi patients visiting India for medical treatment has plummeted by up to 50% due to political unrest in Bangladesh. This downturn has impacted revenues for Indian hospitals. Pharma exports to Bangladesh are also at risk, as the country sources 30% of its pharmaceutical ingredients and raw materials from India, potentially affecting medication availability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4OfBgu8
via IFTTT

Read More

ICMR-led study estimates 10-year risk of developing heart disease in adults in India

An ICMR-led study has found that unemployed adults in India have a significantly higher risk of developing heart disease over the next decade. The research analyzed nearly 4,500 adults aged 40-69 years, showing that men and urban residents have higher risks. High blood sugar and obesity also contribute to increased cardiovascular risks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Vv3FZJQ
via IFTTT

Read More

Struggling with monsoon joint pain? These foods can help

Here are eight foods that can help naturally reduce joint pain during the monsoon season:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hazv3NY
via IFTTT

Read More

Alkem arm ties up with Exactech for knee, hip replacement implants

Alkem Laboratories has announced a partnership through its subsidiary, Alkem MedTech, with US-based Exactech Inc to manufacture and market large joint implants in India. The deal grants Alkem MedTech marketing rights for Exactech's implant brands, including Truliant, Optetrak, and Logic Fit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dIxBQVv
via IFTTT

Read More

USFDA flags Telangana unit of Aurobindo Pharma arm

The letter, issued on August 15, was later made public by the USFDA, which stated that there was failure to ensure the accuracy of data in records for both production and process simulations, i.e. media fills. Media fill is a microbiological test to help prevent contamination during drug production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NHPy18o
via IFTTT

Read More

Scheme to bolster medical device industry to roll out soon: Pharma Secretary

The Department of Pharmaceuticals will launch a new scheme within a month to strengthen the domestic medical device industry, according to Secretary Arunish Chawla. The initiative, developed after extensive consultations, aims to reduce import reliance and promote self-reliance. The scheme has secured in-principle approval from the Finance Ministry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TSE3aNR
via IFTTT

Read More

Indoco Remedies gets USFDA nod to market Lofexidine tablets with 180 days exclusivity

Indoco Remedies Ltd was granted approval from the USFDA to sell its generic Lofexidine tablets, used for opioid withdrawal. This approval includes 180 days of market exclusivity. The company plans an immediate US launch, manufacturing the product in Goa. Expected sales are estimated at USD 15.59 million, with significant growth anticipated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r79GXut
via IFTTT

Read More

Mpox vaccine coming soon, says Covishield manufacturer SII's CEO Adar Poonawalla

Adar Poonawalla of the Serum Institute of India announced that the company was developing a Mpox vaccine, with results expected within a year. The government issued isolation guidelines for suspected cases, and the NIV in Pune tested samples. Experts highlighted concerns about the new CLADE 1B lineage but did not foresee a lockdown.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yEv0KkF
via IFTTT

Read More

Ipca Labs expects its US generics sales to touch $200 million soon

Ipca Laboratories, after resolving regulatory hurdles and integrating Unichem, is set to re-enter the US generics market aiming for $200 million in revenue within 12-18 months. The focus is on commercializing existing products after an import ban by the US FDA was lifted. Unichem has shown profits following these efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5h9bpUH
via IFTTT

Read More

Serum Institute says working to develop Monkeypox vaccine

The World Health Organisation on August 14 declared the Mpox outbreak a public health emergency of international concern. The move came after a sudden increase in cases was recorded in parts of Africa. In India, around 30 Mpox cases have been detected since 2022. The most recent case in the country was reported in March 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GYeiprF
via IFTTT

Read More

Bloated every morning? Try these home remedies for gas relief

Waking up with a bloated stomach can ruin your day. Morning gas, often caused by diet and stress, can be eased with natural remedies like ginger tea, warm lemon water, or fennel seeds for quick relief.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j4UAYb0
via IFTTT

Read More

Granules India gets USFDA nod for generic Glycopyrrolate oral solution

Granules Pharmaceuticals Inc, a subsidiary of Granules India, has received approval from the USFDA for a generic Glycopyrrolate oral solution meant for pediatric patients with neurological conditions associated with drooling. The medication is bioequivalent to Cuvposa Oral Solution by Merz Pharmaceuticals and has a strength of 1mg/5mL.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZqfeGoK
via IFTTT

Read More

Operation buyout: KKR, TPG, and other PE firms eye purchase of India's largest cardiac stent maker SMT

Morgan Stanley PE Asia and Samara Capital collectively own 49% of the company while Kotak Pre IPO Opportunities Fund holds 6%. The Kotadias, the company's promoters, own the remaining 45%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/13F4CcZ
via IFTTT

Read More

Health ministry approves 25% enhancement in security deployment at central hospitals

Amid protests following a trainee doctor's alleged rape and murder in Kolkata, the Health Ministry increased security at Union hospitals by 25%. Officials noted that existing state laws already protect healthcare workers. A new committee will examine hospital security and facilities. Authorities urged striking doctors to resume work to avoid affecting patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RerqNlC
via IFTTT

Read More

Aurobindo Pharma to commercialise China plant in third quarter of FY25: CFO

Aurobindo Pharma's China facility is set to start production in the next quarter, with full-scale output expected in the next fiscal year. The company plans to roll out small volumes in November-December, ramping up in January-March. Chief Financial Officer Santhanam Subramanian anticipates commercialisation in Q3 FY25 and volume production in FY26. The company is also progressing with Pen-G commercialization and aims for an EBITDA margin of 21-22%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x5Pmwfy
via IFTTT

Read More

Indian govt needs to trim citizens' waist size for the sake of economy

India's Economic Survey 2023-24 warned that increasing obesity rates could hinder the country's economic potential. Experts urged the government to promote healthier lifestyles through better diet, physical activity, and monitoring of health parameters. Emphasizing waist circumference and BMI, they suggested that addressing obesity is crucial to reaping India's demographic dividend.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hy7qT3w
via IFTTT

Read More

PM Modi monitoring Mpox status; meeting takes stock of preparedness

Prime Minister Narendra Modi has been monitoring the Mpox situation with no current cases in the country. A high-level meeting assessed the risk of a major outbreak as low. Experts recommended screening travelers and using existing COVID-19 infrastructure to contain potential cases. Transparent reporting and international collaboration were emphasized.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aK3xu1Y
via IFTTT

Read More

Baba Ramdev criticises 'toxic' allopathy medicines that 'killed' millions of Indians

Baba Ramdev voiced his opposition to allopathy, claiming millions in India have died from synthetic drugs. At a press conference, he highlighted the need for medical autonomy and a swadeshi revolution through Patanjali to achieve economic and medical freedom. He accused foreign pharmaceutical companies of creating dependency on harmful medications and stressed the importance of natural healthcare practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4P7e6Du
via IFTTT

Read More

Pharma Department discusses 'dumping' with glovemakers

Domestic glovemakers alleged that gloves from countries like Thailand, Malaysia and China are being dumped in India under different non-medical product codes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/19HqnAo
via IFTTT

Read More

Ipca launches new topical therapy against diabetic foot ulcer

Ipca Laboratories introduced Diulcus, a topical gel designed to treat diabetic foot ulcers, priced at Rs 1365 per pack. The gel is based on repurposed beta blocker Esmolol. Approved after clinical trials, the product showed promising ulcer closure rates, with Ipca targeting a substantial market share within three years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uZ9mpIs
via IFTTT

Read More

Domestic pharmaceutical retail market grows 11 per cent in July

The domestic pharmaceutical retail market saw an impressive 11% growth in July, attributed to increased sales of anti-infectives and pain relief due to rising flu and viral infections. Antibiotic Augmentin led sales at Rs 72 crore and topped the charts. Overall market valued at Rs 2,22,906 crore, showing 7 per cent growth in June. Sun Pharma maintained a top position, with Indian companies growing at 11.4 per cent and MNCs at 10.2 per cent in July. Analysts predict a 10 per cent growth driven by demand for acute therapies like anti-infectives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vSwthmb
via IFTTT

Read More

Aurobindo Pharma's Eugia Unit-3 gets warning letter from USFDA, shares fall

Aurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing unit in Telangana. This followed an earlier inspection that resulted in an 'Official Action Indicated' status. Aurobindo affirmed that current US supplies are unaffected and emphasized their commitment to enhancing compliance with regulatory standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9jPg7Sa
via IFTTT

Read More

AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fight

On Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $107.5 million award against AstraZeneca. Pfizer had claimed AstraZeneca's Tagrisso infringed these patents. Judge Kennelly's ruling found the patents lacked sufficient written descriptions and were not reproducible by a skilled scientist. This decision dismisses the damages awarded in May and affects Pfizer’s ongoing patent infringement claims. The case, Wyeth LLC v. AstraZeneca Pharmaceuticals LP, was heard in the District of Delaware.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bQkDPxv
via IFTTT

Read More

Aurobindo may take its injectable unit public

Aurobindo Pharma is revisiting plans to sell a strategic stake in its injectable unit, Eugia Pharma Specialities, focusing on an IPO. Previously hampered by valuation issues with private equity, the process faces new hurdles due to USFDA observations. Eugia aims to reach $600 million in revenue this fiscal year. Regulatory issues at Unit-3 remain a concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NEiOlVA
via IFTTT

Read More

Nishkala Healthcare acquires Navi Mumbai's Suasth Hospital under IBC process

Nishkala Healthcare acquired Suasth Healthcare Foundation's 400-bed hospital in Navi Mumbai for Rs 189 crore under IBC. Funded through Rs 73 crore in equity and bank loans, the purchase follows the hospital's admission into insolvency. Nishkala aims to enhance the hospital’s value and expand into medical education.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JZlsSpE
via IFTTT

Read More

Alembic gets USFDA nod for generic medication

Alembic Pharmaceuticals announced approval from the USFDA to market Dabigatran Etexilate Capsules (110 mg) for deep vein thrombosis prophylaxis, equivalent to Pradaxa Capsules. The company now has 211 ANDA approvals. Shares closed 3.17% lower at Rs 1,076 on the BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ugt7MJ5
via IFTTT

Read More

Southern states witness majority heart transplants owing to more donations

Southern states in India lead in heart transplantation as per Notto data. Tamil Nadu topped the list at 70 transplants, followed by Karnataka, Maharashtra, Gujarat, and Telangana. South India receives more heart donations due to increased deceased donations. India recorded 1,099 heart donations in 2023, with Telangana leading at 252, followed by Tamil Nadu and Karnataka. Dr YK Misra noted the importance of deceased donors for heart transplants. He highlighted the need for amendments to organ transplant laws in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TaM8EzU
via IFTTT

Read More

Biocon arm's growth formula: US rollouts & debt reduction

Biocon Biologics planned to introduce six new biosimilar products in the US in the next two years, subject to regulatory approval. They emphasized debt reduction and cost optimization, having paid $175 million out of $335 million for a key acquisition. Their revenue increased 3% in Q1FY25 due to gains in the biosimilars market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ModbxCQ
via IFTTT

Read More

SSUHS signs MoU with Novo Nordisk Foundation

Srimanta Sankaradeva University of Health Sciences and Novo Nordisk Foundation signed an MoU to enhance Assam's health sector. The deal aims to improve nursing education, including an Education Innovation Unit and Simulation Lab. The partnership provides initial financial support of Rs 6 crore and promises further collaboration to improve nursing education and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oOHmLUy
via IFTTT

Read More

Revenue of domestic API firms to see 7-8 pc increase by 2029: Report

The revenue of domestic active pharmaceutical ingredients (API) producers in India is projected to grow by 7-8% annually by 2029, according to a report by ICRA. The rating agency estimates that revenues will increase from USD 13-14 billion in 2023, driven by the pharmaceutical formulations industry and factors like an aging population, rising chronic diseases, and contract manufacturing demand. The operating profit margins of API firms are expected to improve in FY2025. Despite past challenges, including volatile earnings due to rising raw material costs and supply chain issues, the industry is poised for steady growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LqUdHJ9
via IFTTT

Read More

Dr Reddy's gets establishment inspection report from USFDA for Visakhapatnam units

Dr Reddy's Laboratories Ltd has obtained an Establishment Inspection Report from the USFDA for its Duvvada units, now classified as Voluntary Action Indicated. The units underwent an inspection from May 8 to May 17, 2024, which led to a Form 483 with observations. Dr Reddy’s planned to resolve the issues within the given time.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AqXWD6l
via IFTTT

Read More

As monsoon takes hold, anti-infective, respiratory drugs' demand surges

Monsoon led to a surge in demand for respiratory, anti-infective, and anti-malarial products. The respiratory market saw a notable increase in Poractant Alfa usage. Anti-malaria medicines experienced significant growth, driven by seasonal patterns. Core therapeutic areas like cardiac, respiratory, and gastro contributed to the overall market growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xH9JzqL
via IFTTT

Read More

What not to drink: 7 beverages that can worsen fatty liver

If you're looking to manage or avoid fatty liver, it's important to be cautious about your drink choices. Here are seven drinks that are generally considered worse for fatty liver:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/egYRT6t
via IFTTT

Read More

At over 10 cr, India’s diabetic population is surging, yet the country lags behind in prescribing new medicines

Priya Rao experienced confusion and worry after fainting and receiving different diabetic medications from two doctors. The first doctor followed global guidelines, while the second used Indian ones, stabilizing her condition. The case underscores different diabetic treatment protocols and the importance of tailored patient care in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2wdsQBP
via IFTTT

Read More

Explore lesser-known Indian nuts: Chilgoza, Chiraunji & their benefits

India boasts a rich tradition of nuts in cooking and medicine. While almonds and cashews are common, lesser-known nuts like chilgoza and chiraunji offer unique flavors and significant health benefits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FpzmhJD
via IFTTT

Read More

Hospital chain Medanta lines up Rs 1,200 crore for Mumbai entry

Global Health, operator of Medanta hospitals, is set to build a 500-bed super specialty hospital in Mumbai with an investment of ₹1,200 crore. The project, funded equally by debt and internal accruals, will be completed in 3-4 years. Medanta recently acquired the land in Oshiwara through a public auction.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fdCMeVA
via IFTTT

Read More

Boost kidney health with these 7 detoxifying foods

Detoxifying your kidneys is important for overall health. Here are seven foods that are particularly beneficial for kidney health:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dQBwhRk
via IFTTT

Read More

India eases drug approval process, waives local trials for advanced therapies

In a major policy shift, the Indian government has waived local clinical trial requirements for drugs and vaccines approved by major international regulators (US, UK, Japan, Australia, Canada, EU). This move, aimed at expediting access to advanced therapies like CAR T-cell therapy and Sacituzumab govitecan, still ensures post-marketing surveillance by the CDSCO.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jrOfeKl
via IFTTT

Read More

Biotech giant Amgen plans to open to technology & innovation centre in Hyderabad

US biotech giant Amgen announced plans to open a new technology and innovation site in Hyderabad, India. The site will be located in HITEC City and will occupy six floors of the RMZ Spire Tower. It is expected to be operational in Q4 2024 and has the potential to accommodate up to 3,000 people.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dRoODCN
via IFTTT

Read More

Fortis Healthcare to buy out PE funds from diagnostics arm Agilus

Fortis Healthcare has acquired a 34% stake in Agilus Diagnostics from private equity firms Jacob Ballas and IFC. This transaction valued Agilus at around ₹5,000 crore and increased Fortis's holding from 57% to 91%. Agilus operates 413 laboratories and faced expansion challenges due to investors' reluctance and rising competition from new-age online players.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z95ukRJ
via IFTTT

Read More

Bajaj could make a difference in healthcare space

The Bajaj group's move into the hospital industry promises to influence the Indian healthcare sector. Private hospitals have shown growth and investor interest has risen post-pandemic. Bajaj plans to establish hospitals in metropolitan areas but will face significant hurdles such as high costs and a lack of medical professionals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5XqVdFj
via IFTTT

Read More

India waives clinical trial requirement for drugs approved in developed markets

India has waived clinical trial requirements for new drugs with significant therapeutic advances that have been approved in the US, UK, Japan, Australia, Canada, or the EU. The Central Drugs Standard Control Organisation (CDSCO) stated that this move aims to speed up drug availability, especially for rare diseases, pandemics, and special defence needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gDf06rm
via IFTTT

Read More

India's Fortis Healthcare chairman Ravi Rajagopal resigns

Ravi Rajagopal has resigned as chairman of Fortis Healthcare, effective Sept. 30, due to increased commitments in the U.K. and other regions. He will also step down from the Corporate Social Responsibility Committee. Rajagopal became chairman in June 2018 when Fortis was dealing with significant challenges, and he found his tenure personally fulfilling.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Yp5NGrI
via IFTTT

Read More

BHU study on Covaxin had serious methodological flaws as per ICMR: Prataprao Jadhav

The Indian Council of Medical Research (ICMR) reviewed a study on the long-term safety of Covaxin in adults and adolescents, conducted by Banaras Hindu University, and found significant methodological flaws. Minister of State for Health Prataprao Jadhav informed the Rajya Sabha that the study lacked a control group of unvaccinated individuals, making it impossible to link reported events to the vaccine. The study, published in May, also lacked background rates and baseline participant information. ICMR has requested the removal of its acknowledgment from the study and asked the journal to retract the paper due to unsupported conclusions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ClH27uW
via IFTTT

Read More

Pharma industry urges govt for stable drug pricing policy

The Organisation of Pharmaceutical Producers of India (OPPI) has called for a stable and predictable drug pricing policy, urging the government to avoid using Para 19 of the Drug Pricing Control Order (DPCO), which allows significant price reductions in the public interest.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/muJ9vQw
via IFTTT

Read More

Hamara Hospital! Bajaj plans a healthcare ride

The Bajaj Group, worth ₹1.46 lakh crore, initiated steps to venture into the healthcare industry by setting up hospitals in metros. Overseen by Nirav Bajaj, the project will be housed in a new company, with phased investments based on milestones. This marks the group's first major diversification since Rahul Bajaj's death in 2022.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EzQ1l3D
via IFTTT

Read More

New data reveals why patients from the US and UK are flocking to India for organ transplants

In 2023, India conducted 1,851 organ transplants for foreign nationals, accounting for nearly 10% of all transplants. The majority of these transplants took place in Delhi, Rajasthan, and West Bengal. Foreign patients primarily seek living donor transplants due to lower costs and strict vetting protocols. Deceased donations are rare and usually reserved for Indian recipients. India set records with over 1,000 deceased donors and 18,378 transplants, highlighting its growing role as a hub for organ transplants.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ULAde19
via IFTTT

Read More

Sun Pharma's hair loss drug in the cross hairs in US

Leqselvi is used for the treatment of alopecia areata, an autoimmune disease that leads to hair loss, and was approved by the US Food and Drug Administration (USFDA) last week. Sun Pharma has been making preparations for months to launch the drug in July, but an injunction motion by the American drugmaker lncyte Corporation in the US District Court for the District of New Jersey has put the brakes on the launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lwrhX9v
via IFTTT

Read More

Bharat Biotech credited ICMR, NIV as Covaxin co-inventors after missing them initially: Government

Responding to Trinamool Congress member Sougata Roy, who had asked whether the government took any punitive action against the company for not mentioning the names of ICMR and NIV in the patent application, the Union Health and Family Welfare Minister gave a detailed reply. There was a joint Memorandum of Understanding (MoU) between ICMR, NIV and Bharat Biotech for the development of Covaxin, he said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yjXgSFt
via IFTTT

Read More

Sanofi gets drug regulator nod to market RSV therapy in India

French drugmaker Sanofi announced on Thursday that it has received approval from India's Central Drugs Standard Control Organization (CDSCO) to market its novel therapy, Beyfortus, in India. The therapy is aimed at protecting newborns and infants from respiratory syncytial virus (RSV).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0YUjf7
via IFTTT

Read More

Unaprime buys Tata Healthcare's 43.5% in Lokmanya Hospitals

Lokmanya Hospitals has five hospitals located in Pune, Pimpri-Chinchwad and Kolhapur. The hospitals have an existing capacity of 300 beds and plan to expand to 500 beds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OiGIPZq
via IFTTT

Read More

Zydus gets Mexican regulatory approval to market cancer treatment product

The product is used in the treatment of breast cancer and advanced gastric cancer. Breast cancer has become the most diagnosed cancer in Mexico, overtaking prostate and colorectal cancers, the company added. Developed in-house by the research team at the Zydus Research Centre (ZRC), the Trastuzumab biosimilar was launched in 2016 in India under the brand name Vivitra. Since then, an estimated 1 lakh patients have been treated with the therapy, the company added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oJMvAZG
via IFTTT

Read More

Heavy metal in most chocolates may not pose health risk, researchers say

Some consumer groups and independent test agencies have previously reported heavy metal contamination in cocoa products such as dark chocolate, with possible causes being the type of soil where cocoa is grown and industrial processing. Researchers at the George Washington University School of Medicine and ConsumerLab.com found that 70 of the 72 cocoa-containing products they analyzed fell below limits set by the Food and Drug Administration (FDA) for lead contamination.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S65bq1T
via IFTTT

Read More

TA Associates, 2 others offer to buy into Eye Foundation

TA Associates, Multiples PE, and KKR have made non-binding offers to invest ₹830 crore for a 25% stake in Eye Foundation, valuing it at ₹3,360 crore. With an expected EBITDA of ₹140 crore for FY25, the eye care chain's asset-light, scalable model is drawing substantial private equity interest.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NpDboAt
via IFTTT

Read More

Govt plans crackdown on lookalike drug brands

According to people in the know, the government is likely to consider as valid only the brand names which were approved first by the regulator. Other same or similar sounding and lookalike brands will not be allowed to be marketed. Drug makers will soon be asked to upload formulation details along with the brand names of their products on the government's portal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QW0kRu4
via IFTTT

Read More

Drug MNCs for keeping patient aid plan out of trade margin formula

The Organisation of Pharmaceutical Producers of India (OPPI) recommended excluding Patient Assistance Programmes (PAPs) from Trade Margin Rationalisation to maintain affordability for patients. They noted that PAPs are crucial for providing access to expensive drugs, especially for oncology and rare diseases. OPPI also sought exemption for patented and orphan drugs from government-set price controls and opposed post-patent price cuts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7szSUgu
via IFTTT

Read More

Narrative claiming vapes, e-cigarettes healthier alternatives are misleading: Experts

Experts have raised concerns about the portrayal of e-cigarettes as healthier alternatives to tobacco, warning they can lead to traditional tobacco use among youth. India's ban on these products has potentially prevented millions of addictions. Public awareness and stringent regulations were emphasized as necessary to tackle this issue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SUOu9z2
via IFTTT

Read More

Cipla expects to commence supplies to US from China plant later this year

Cipla plans to start supplying from its China facility to the US market by the second half of the current fiscal year, following USFDA approval. The company is resolving regulatory issues with its domestic plants and focusing on new therapeutic areas and tech-based solutions. Cipla is also addressing antimicrobial resistance and expanding its digital health initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pvuqdyt
via IFTTT

Read More

Mankind Pharma taps Barclays and Deutsche Bank for Rs 13,630 cr acquisition of Bharat Serums & Vaccines

Mankind Pharma has appointed Barclays and Deutsche Bank to arrange financing for its Rs 13,630 crore acquisition of Bharat Serums & Vaccines. The deal will be partly funded through Rs 4,000 crore in internal accruals and the rest via debt. Mankind’s board approved raising ₹7,500 crore in equity and increasing the borrowing limit to ₹12,500 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xr74ZfY
via IFTTT

Read More

Textiles and pharma PLI schemes likely to see longer product list

The cabinet was set to decide on expanding the production-linked incentive (PLI) schemes in sectors like textiles, food processing, and pharmaceuticals to include more products. Meanwhile, the budget for PLI schemes increased to `16,092 crore for FY25. Textile PLI might see a lower investment threshold, with more man-made fabric products and apparel possibly being added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/31ANVRe
via IFTTT

Read More

Mankind to use debt, internal accruals to fund BSV buyout

Mankind Pharma announced a ₹13,630 crore acquisition of Bharat Serums and Vaccines (BSV) to be funded through internal accruals and a mix of debt and equity. This strategic move will make them leaders in the gynaecology-fertility segment. The acquisition aligns with their goal to expand in high-potential areas and is expected to boost earnings from the second year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kS16e2Z
via IFTTT

Read More

Sun Pharma's drug to treat alopecia areata gets USFDA nod

Sun Pharmaceutical Industries Ltd announced that the USFDA has approved its drug LEQSELVI (deuruxolitinib) for treating adults with severe alopecia areata. The approval is based on Phase 3 clinical trials involving 1,220 patients. LEQSELVI provides a new treatment option for patients with significant hair loss due to this autoimmune disorder.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i9NwTQc
via IFTTT

Read More

General Atlantic, other PE funds in talks for majority stake in AIMS

General Atlantic and KKR are among several private equity firms vying for a majority stake in Faridabad-based Asian Institute of Medical Sciences (AIMS), valued at approximately ₹1,500 crore. Other interested parties include Growtheum Capital and Everstone Capital, while IndiaRF has withdrawn from the bidding.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0ul8Avn
via IFTTT

Read More

Mankind Pharma to acquire Bharat Serums from Advent International for Rs 13,630 cr

Mankind Pharma announced its acquisition of Bharat Serums and Vaccines Limited (BSV) from Advent International for approximately Rs 13,630 crore. This deal positions Mankind Pharma as a leader in the Indian women's health and fertility drug market, expanding its portfolio to include high-entry barrier products in critical care with established R&D technology platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ac7FyeD
via IFTTT

Read More

Diabetes management in the time of urbanisation: An Indian perspective

India's rapid urbanisation and economic growth have led to a spike in chronic diseases, including diabetes, particularly in rural areas. Increased disposable income, sedentary lifestyles, and unhealthy eating habits are driving this trend. Addressing these health challenges requires a consistent approach prioritising early detection, balanced diets, and education on diabetes management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QCKaDGf
via IFTTT

Read More

Mankind Pharma is frontrunner in Bharat Serums bid

Mankind Pharma is in talks to acquire Bharat Serums & Vaccines Ltd., a biopharmaceutical company with brands like Manforce Condoms and Prega News pregnancy tests. The target company could be valued at around $1.5 billion. Advent International, which acquired a majority stake in Bharat Serums in 2019, is looking to exit and return liquidity to investors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i5WhXza
via IFTTT

Read More

Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement

Mayne Pharma sued India's Sun Pharma for allegedly infringing patents on IMVEXXY, a drug for menopause-related vaginal pain. The lawsuit was filed after Sun Pharma sought FDA approval for a generic version. This action might delay FDA approval for Sun Pharma by 30 months under the Hatch-Waxman Act.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VMJpB8b
via IFTTT

Read More

Experts say a twice-yearly injection that offers 100% protection against HIV is 'stunning'

The shots made by U.S. drugmaker Gilead and sold as Sunlenca are approved in the U.S., Canada, Europe and elsewhere, but only as a treatment for HIV. The company said it is waiting for results of testing in men before seeking permission to use it to protect against infection.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1YQGMuj
via IFTTT

Read More

Budget 2024: Cancer patients get relief but senior citizens missed the attention

The Union Budget 2024, while significantly increasing health sector funding to ₹90,959 crore, failed to address the BJP’s poll promise of including senior citizens above 70 in Ayushman Bharat-PMJAY. The budget features customs duty exemptions for three cancer drugs and changes to basic customs duty for X-ray equipment. Reactions from healthcare leaders underscore the budget's focus on improving accessibility and infrastructure. However, the omission of the senior citizens' health cover highlights a key unfulfilled promise, leaving a gap in comprehensive healthcare improvements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OZ2rMTY
via IFTTT

Read More

Govt mulls dropping quality tests for cough syrups from developed market-approved plants

The proposal, which follows a representation from a stakeholder, suggests that testing at the prescribed laboratory may be waived for cough syrups being exported to the US, UK, Canada, EU, Japan, Australia, Singapore, Republic of Korea and Switzerland.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vAmWe7I
via IFTTT

Read More

Drugs regulatory body may waive testing requirement for cough syrups exported to certain countries

CDSCO mulls exempting cough syrups from testing before export to select countries. Quality concerns arose last year prompting mandatory testing. Stakeholders seek waiver, while data shows some batches failed quality standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/INBWwY6
via IFTTT

Read More

Budget 2024: Government proposes to fully exempt 3 cancer drugs from customs duty

The government proposes to cut custom duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil. Finance Minister Nirmala Sitharaman also proposed changes in the basic customs duty (BCD) on x-ray tubes and flat panel detectors for use in medical x-ray machines under the phased manufacturing programme, so as to synchronise them with domestic capacity addition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GMXNxVQ
via IFTTT

Read More

Economic Survey: Mental health issues rising, holistic approach required

The Economic Survey highlights the increase in mental health issues in India, emphasizing the need for a community-based approach. Urban areas show higher prevalence than rural areas. Health expenditure has grown significantly. AB PM-JAY scheme estimated to save over 1.25 lakh crore for disadvantaged families.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5EYjbXe
via IFTTT

Read More

Over 100 cough syrup makers fail quality test

A government report reveals that over 100 pharma units' cough syrup samples failed quality tests, showing the same toxins linked to child deaths in Gambia, Uzbekistan, and Cameroon. The Central Drugs Standard Control Organisation's analysis found 353 out of 7,087 batches sub-standard,. Issues include unsecured supply chains and inadequate testing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l9KkEIq
via IFTTT

Read More

Next leg of pharma sector growth necessitates skill advancement, innovation: Eco Survey

Economic Survey 2024: The domestic pharmaceutical industry in India needs skill advancement, innovation, and a robust supply chain to meet the expected segment size of USD 130 billion by 2030, according to the Economic Survey 2023-24 tabled in Parliament on Monday. Currently, the Indian pharmaceutical market is valued at around USD 50 billion, making it the world's third-largest by volume.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QWh2IU0
via IFTTT

Read More

Sanofi initiates voluntary recall of Allegra, Combiflam suspensions due to contamination in some batches

Sanofi has announced a "temporary halt" on the sales of Allegra Suspension and Combiflam Suspension in India, due to microbiological contamination. The precautionary recall, affecting specific batches, aims to ensure safety while investigations continue. These medicines, commonly used for treating allergies and pain in children, are being recalled from distributors, hospitals, and retailers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NDdXI9r
via IFTTT

Read More

Pharma MNCs seek relief from price control for patented drugs

The Organisation of Pharmaceutical Producers of India (OPPI) is requesting exemptions for patented and orphan drugs from government price controls. They argue that current regulations hinder innovation and want more control over pricing post-patent expiry to provide economic incentives for inventors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dmMxwFP
via IFTTT

Read More

Kerala: 14-year-old dies from Nipah virus; causes, symptoms, and treatment explained

Amid the rising concerns over the spread of the virus, listed below are the causes, symptoms and treatment:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UFehr9k
via IFTTT

Read More

Budget FY25: Pharmaceuticals sector needs a major boost with increased focus on R&D and innovation

The Union Budget 2024-2025, pivotal for India's Amrit Kaal vision, aims to foster economic growth and inclusive development. The budget is expected to boost infrastructure, streamline bureaucracy, and promote technology and innovation. Emphasis on the pharmaceutical sector, with increased allocations, can drive India's economic and healthcare advancements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x8HpKwZ
via IFTTT

Read More

CCI approves two acquisitions involving Arjas Steel, Suven Pharmaceutical

The Competition Commission of India (CCI) has approved two major acquisitions involving Arjas Steel Private Limited (ASPL) and its wholly owned subsidiary, Arjas Modern Steel Private Limited (AMSPL). The acquisition will be carried out indirectly by The Sandur Manganese & Iron Ores Limited (SMIORE) and BAG Holdings Private Limited (BHPL), as per an official statement by CCI.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1AbtFnZ
via IFTTT

Read More

Dr Reddy's inks licensing pact with Takeda to sell gastrointestinal drug

New Delhi: Dr Reddy's Laboratories, a Hyderabad-based firm, and Takeda Pharmaceutical entered a non-exclusive licensing pact to market 10mg and 20mg Vonoprazan tablets, a PCAB for reflux esophagitis and acid peptic disorders, in India. CEO MV Ramana highlighted the strategic collaboration. Shares rose 0.33% to Rs 6,665.10 on BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wtplLcq
via IFTTT

Read More

USFDA classifies Zydus Lifesciences Jarod unit as 'official action indicated'

Zydus Lifesciences Ltd has been classified as "official action indicated" by the US Food and Drug Administration (FDA) for its Jarod injectables manufacturing facility in Gujarat. The FDA's inspection, conducted between April 15 and 23, 2024, suggests the facility may withhold approval for pending product applications or supplements until outstanding observations are resolved.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8hj1TuK
via IFTTT

Read More

SC dismisses Sun Pharma's plea against NPPA's demand notice of Rs 4.65 cr for overcharging drug

The Supreme Court dismissed Sun Pharma's plea against a demand notice of Rs 4.65 crore by NPPA for overcharging for the drug Roscilox, upholding the Delhi High Court's decision. Sun Pharma challenged the demand for overcharged amount under DPCO, with the court finding no merit in the appeal. It noted Sun Pharma's direct purchase from the manufacturer and overlapping identities with Oscar Laboratories Pvt. Ltd.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KNJj1cU
via IFTTT

Read More

Sanofi looking to expand India hub with Rs 3.6k-cr push

The Hyderabad GCC will support Sanofi's global operations spanning commercial, manufacturing, supply chain research and development (R&D) and digitalisation. The GCC in India will help the company bring some of outsourced functions in-house, giving it more control over critical operations like manufacturing, commercial and R&D.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NYW2Ldg
via IFTTT

Read More

USFDA approves Glenmark Pharma's seizure treatment drug

New Delhi-based Glenmark's USFDA-approved 15 mg and 25 mg Topiramate capsules, equivalent to Janssen's Topamax, will be marketed by Glenmark Pharmaceuticals Inc., USA. Topamax had recorded annual sales worth USD 21.9 million per IQVIATM (till May 2024). Glenmark's US portfolio has 198 products, 50 ANDAs pending, and seeks growth through external development partnerships.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y83YDJS
via IFTTT

Read More

Mankind Pharma competes with EQT-ADIA combo for Rs 14,000 cr buyout of BSV Group from Advent

The buyout of BSV Group (formerly Bharat Serum & Vaccines Ltd) is contested by Mankind Pharma and EQT with ADIA, each offering around Rs 14,000 crore ($1.6 billion). This acquisition, one of India's largest pharma buyouts, will significantly impact the domestic market and mark a successful exit for Advent International.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cOQgE4K
via IFTTT

Read More

Pharma companies against plan to bring nutraceuticals under drug regulator

Controversy arises as government considers shifting nutraceuticals to drug regulatory authority from FSSAI oversight. Industry experts express reservations and call for detailed discussions. Nutraceutical segment set to reach $18 billion in India by 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f4SrmWX
via IFTTT

Read More

Cipla gets Rs 773 crore demand notice from I-T department

The additional demand was raised for disallowances related to deduction of profits and gains derived from the business of developing, maintaining, and operating the infrastructure facilities, expenditure on R&D, business or professional expenses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n8exAop
via IFTTT

Read More

Mankind Pharma in licensing pact with Takeda to market acidity drug Vonoprazan in India

Mankind Pharma partners with Takeda to introduce Vonoprazan for GERD, oesophagitis, ulcers, and Helicobacter pylori in India. EVP Ramesh stresses business growth. Collaborations with AstraZeneca (Symbicort) and Novartis (Neptaz) enhance their strategy. In-licensing, including royalties on sales, expands domestic formulations using local sales networks, improving access to innovative therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7TPOpaE
via IFTTT

Read More

Supreme Court upholds NPPA's Rs 4.65 cr recovery from Sun Pharma for drug price violation

The Supreme Court upheld NPPA's Rs 4.65 crore recovery from Sun Pharma for Roscilox overpricing (April 1996 - July 2003). The appeal was rejected owing to inconsistencies and Paragraph 13 of DPCO. Delhi HC found overlap with Oscar Laboratories. Sun Pharma, acting as dealer and distributor, lacked documentation, with direct contact as per DPCO definitions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yFgX2Bj
via IFTTT

Read More

Lupin divests women's health specialty business in US to Evofem Biosciences for nearly $84 mn

Lupin announced the sale of its US commercial women’s health specialty business, focusing on Solosec, to Evofem Biosciences. Solosec, an FDA-approved single-dose treatment for bacterial vaginosis and trichomoniasis, is the key product involved. The deal includes potential payments up to USD 84 million based on future milestones.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d1Gyk7c
via IFTTT

Read More

Diabetes and heart disease: A call for integrated management

Statistics show low treatment target compliance among Indian diabetes patients, increasing heart disease risks. Timely screening and weight management are crucial for better health outcomes. Learn more about the importance of integrated management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qZ4frMo
via IFTTT

Read More

Pharma industry seeks relief from price cap rule for cheap drugs

India’s FoPE seeks a 10-year exemption for patented and low-cost drugs from price controls. Requests include DPCO and 12% GST adjustments due to 15-130% ingredient cost rises. Presenting to the DoP secretary, FoPE cites working capital issues prompting overseas research. Supported by IPA, Harish Jain stressed necessary revisions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C51tja2
via IFTTT

Read More

Top 5 tips to prevent hair loss in monsoon

Here are five tips to prevent hair loss during the monsoon season:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wcQRsKN
via IFTTT

Read More

Gel polish, acrylic nails: How a booming industry can cause cancer

Nail art, acrylic nails and gel manicures are becoming increasingly popular, with celebrities including Kylie Jenner, Ariana Grande and Rihanna often donning them.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lGHhx7X
via IFTTT

Read More

Nutraceuticals may get cheaper as panel looks to regulate prices

The Indian government is contemplating bringing nutraceuticals under price control to enhance affordability for consumers. Currently regulated by the Food Safety and Standards Authority of India (FSSAI) without price controls, these products, often marketed as over-the-counter health supplements, face scrutiny for high pricing. Officials argue that some companies charge exorbitant prices by repackaging pharmaceutical ingredients into nutraceuticals. A committee involving various health and regulatory bodies aims to introduce pricing regulations to curb this trend and ensure fair pricing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y6fzRPi
via IFTTT

Read More

MGM Healthcare promoter acquires Vizag's SevenHills Hospital under IBC

The Amravati bench at Mangalagiri of the National Company Law Tribunal approved a ₹171 crore resolution plan against ₹1,361.89 crore admitted claims from creditors, employees, and others. The secured creditors admitted claim was ₹1,273 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/10SbTEY
via IFTTT

Read More

Indian pharma companies faked generic viagra data to gain approval, finds US FDA

FDA's June 18 alert revealed falsified data by Synapse Labs affecting generics like Umedica's Viagra. Europe had earlier warned. Insurers might change coverage. Both Massoud Motamed and Erin Fox highlight ingredient risks. Due to confidentiality, FDA hasn't disclosed all affected drugs, suspended sales, or done significant public outreach. Identified generics include Lupin's Lipitor and Aurobindo's risendronate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IlKyAWv
via IFTTT

Read More

Zydus barred from selling cancer biosimilar, for now

The Delhi High Court has temporarily barred Zydus Lifesciences from selling its breast cancer drug Sigrima, a biosimilar of Roche's Perjeta (pertuzumab), due to a patent infringement lawsuit filed by Roche. The court granted an interim injunction against Zydus after Roche argued that Sigrima and another biosimilar, Womab from Dr Reddy's, violate its patents. Zydus had received conditional approval for its pertuzumab biosimilar but launched it amidst ongoing litigation, prompting the court to intervene to prevent potential market disruption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xIOGgFJ
via IFTTT

Read More

From napkin scribbles to heart pumps, a life-saving breakthrough from casual dinner talk

An Indian surgeon and Australian professor founded Cardiobionic to create affordable heart pumps. Patented prototypes, including a bi-ventricular assist pump, use a non-contact impeller and are undergoing animal tests. Cardiobionic has been funded by Indian investors and others

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5eMz2K0
via IFTTT

Read More

GSK gets restraining order against Elder Laboratories

GSK approached the high court against Elder Laboratories early this year for alleged infringement of trademark, including usage of identical product names, trademarks and packaging. GSK issued several notices to Elder before approaching the court seeking a restraining order.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/irDu2XQ
via IFTTT

Read More

Maharashtra government to bring new law to crack down on bogus pathology labs

The issue concerns the urban development, public health and medical education departments, Samant said. BJP MLA Ashish Shelar said bogus pathology labs were looting money and playing with people's lives. Several collection centres that have come up over the years should be registered, he said, demanding criminal cases against violators.

from Healthcare/Biotech-Industry-Economic Times https://economictimes.indiatimes.com/industry/healthcare/biotech/maharashtra-government-to-bring-new-law-to-crack-down-on-bogus-pathology-labs/articleshow/111600846.cms
via IFTTT

Read More

5 veggie superfoods to boost collagen naturally

Including these veggies in your diet can help maintain healthy skin and support your body’s natural collagen production:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iPgODHf
via IFTTT

Read More

Budget 2024: Is a Rs 10 lakh insurance the vitamin India's healthcare system needs?

The Centre is considering doubling the beneficiary base of the Ayushman Bharat health insurance scheme over the next three years, starting with those aged above 70, alongside raising annual coverage to Rs 10 lakh. These proposals are anticipated in the upcoming Union Budget. The interim Budget increased Ayushman Bharat's allocation to Rs 7,200 crore for secondary and tertiary care, with Rs 646 crore for health infrastructure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/04ziwtk
via IFTTT

Read More

As monsoon sets in, respiratory, malaria drugs see demand rise

The onset of the monsoon in June led to a significant increase in sales of drugs for respiratory, anti-infective, anti-malaria, and gastrointestinal therapies. According to market researcher Pharmarack, these therapies saw double-digit growth compared to June 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/w0zjDOL
via IFTTT

Read More

Budget 2024: Pharma sector seeks tax sops, effective intellectual property rights regime

Union Budget: Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wVlRUab
via IFTTT

Read More

Apollo Hospitals to acquire Rs 103.2 crore stake in subsidiary Apollo Health

"... we wish to inform you that the Company is acquiring 35,12,107 equity shares of Rs 10 each at a price of Rs.294/- per share (including premium of Rs.284/- per share) aggregating to Rs. 1032.60 million by way of subscribing to the rights issue of Apollo Health and Lifestyle Limited, a subsidiary of the Company (AHLL)," the hospital chain company informed stock exchanges on Saturday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Gu98tAS
via IFTTT

Read More

Budget 2024: Drugmakers want Nirmala Sitharaman to prescribe tax relief tablet for the economy

Budget 2024: Indian pharmaceutical companies are looking for tax incentives and financial support in the upcoming Union Budget to boost research on innovative drugs. Industry experts emphasize the importance of thinking creatively and implementing policies to enhance growth in the sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OChbBjz
via IFTTT

Read More

Drugs body flags side effects of heart, Glaucoma medications

The Indian Pharmacopoeia Commission has issued a drug safety alert regarding amlodipine and acetazolamide, highlighting potential adverse reactions. Healthcare professionals are advised to monitor for adverse drug reactions, while patients should be vigilant for any symptoms. Companies may be required to include warnings in drug packaging.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KGPc1kX
via IFTTT

Read More

Fortis designates Prem Kumar Nair as Vice-Chairman

He was appointed Group Chief Executive Officer of IHH Healthcare on October 1, 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J5bECL2
via IFTTT

Read More

Nutrition advocacy NAPi calls for amending regulations for ads of unhealthy foods

Consequences of such advertising are increased intake of unhealthy food products associated with obesity and diabetes, the report said. “India is facing a dubious distinction of persistent under-nutrition among children under five, and a rising trend of obesity and diabetes among grown-ups,” according to the report.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IW2Q6qx
via IFTTT

Read More

Cancer risk and diet: Foods to be cautious about

Certain foods and dietary habits have been associated with an increased risk of cancer. To reduce cancer risk, it is recommended to follow a diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats, while limiting the intake of the foods and drinks listed above. Here are some examples:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8Io51yC
via IFTTT

Read More

Need to sensitise foreign nationals on organ transplant guidelines in India: Health ministry

"It is essential for these foreign nationals visiting India for organ transplant to understand the specific guidelines and legal requirements that regulate the process of organ transplantation in India," Chandra said in the letter addressed to Union Home Secretary Ajay Kumar Bhalla and Union Foreign Secretary Vinay Mohan Kwatra on June 19.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kWHyn0P
via IFTTT

Read More

Inclusive healthcare: H.E. Dr. Noura Khamis Al Ghaithi on Abu Dhabi’s vision beyond borders

In conversation with H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, who outlines the vision of the Abu Dhabi Global Healthcare Week (ADGHW) positioned to serve as an annual platform for inclusive knowledge-sharing and crafting collaborative strategies aimed at delivering positive patient outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VTLs2jE
via IFTTT

Read More

Zydus Lifesciences gets tentative approval from USFDA for BP lowering drug

Zydus Lifesciences announced on Thursday that it has received tentative approval from the US Food and Drug Administration (USFDA) to market its generic Azilsartan Medoxomil tablets, which are used to treat high blood pressure. The USFDA's tentative approval covers Azilsartan Medoxomil tablets in strengths of 40 mg and 80 mg.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zzsh1ad
via IFTTT

Read More

Waiting for a wonder drug? The weight just got longer

Eli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the drug in India in 2025, pending supply. The SEC recommends approval for pre-filled pens and vials, contingent on a phase-IV trial. The Drug Controller General of India will finalize the decision.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DhvRGUm
via IFTTT

Read More

Warning letter: USFDA pulls up Sun Pharma for manufacturing issues at Dadra facility

"Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitise and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the USFDA said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IT1PXKa
via IFTTT

Read More

Living with diabetes: A holistic approach

Combatting diabetes through weight loss is key for reducing risks of heart disease and stroke, emphasizing holistic lifestyle management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qsQ6JwA
via IFTTT

Read More

Weekly-once insulin jab may soon come to India

A new weekly insulin dosage by Novo Nordisk, Insulin Icodec, is on the brink of approval in India, offering potential relief for those who require daily insulin injections. The Subject Expert Committee has recommended permitting the import and sale of this innovative product, expected to revolutionise the insulin market. While further studies are required, doctors anticipate improved patient compliance with this new treatment option.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/It8Biyn
via IFTTT

Read More

Zika virus spreads in Pune: Here's how the virus infects, risks, symptoms, and prevention

Pune faces a rising Zika virus threat with six recent cases, including two pregnant women. Health authorities are intensifying surveillance and mosquito control efforts. Zika, transmitted by Aedes mosquitoes, poses significant risks during pregnancy, potentially leading to severe birth defects. While symptoms are usually mild, caution is advised, especially for expectant mothers. Here’s a comprehensive overview of Zika virus infection, its symptoms, impact on pregnancy, and preventive measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4p0C9nc
via IFTTT

Read More

Understanding Dengue: What is dengue? Symptoms and treatment; Can dengue kill?

Dengue fever is a mosquito-borne viral infection prevalent in tropical and subtropical regions worldwide, including India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d8iYCzW
via IFTTT

Read More

KKR set to acquire Kerala's Baby Memorial Hospitals, make a comeback in hospital segment

KKR & Co plans to acquire a 70% stake in Kerala's Baby Memorial Hospital (BMH) for $300 million, marking its return to the Indian hospital sector. BMH, with 500 beds and expansion plans, is among Kerala’s largest hospitals. This move aligns with KKR’s strategy of expanding healthcare assets in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sOSWHxV
via IFTTT

Read More

US fund Platinum acquires Inventia Health in India foray

Platinum Equity makes its debut in India by acquiring a majority stake in Mumbai's Inventia Healthcare. With a valuation of Rs 2,500 crore, the deal sees PE investors exiting while the promoter retains a minority stake. Platinum Equity, managing over $48 billion in assets, is well-known for its expertise in the healthcare sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZldEqhQ
via IFTTT

Read More

India's healthcare in critical condition: 4 out of 5 public health centers below par, reveals new Govt report

A recent Indian government self-assessment reveals that most public health facilities, including district hospitals and primary centers, fall short of essential standards. Only 20% meet benchmarks for infrastructure and resources, with 42% scoring below 50%. Initiatives aim to bring 70,000 facilities to standard within 100 days, backed by inspections and funding under the National Health Mission. This highlights urgent reforms needed to enhance healthcare nationwide, promising better services and equity in healthcare delivery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sge160z
via IFTTT

Read More

HCG acquires Vizag based cancer hospital for enterprise valuation of Rs 414 crore

HCG, India's leading cancer care chain, acquired a majority stake in Visakhapatnam's Mahatma Gandhi Cancer Hospital for Rs 414 crore. The deal begins with a 51% ownership, aiming to complete 85% in 18 months. The hospital's FY24 revenue was Rs 120.2 crore with an EBITDA of Rs 42.2 crore, expected to boost HCG's annual EBITDA by Rs 3 per share and consolidate its position in the Vizag region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JdwW6tB
via IFTTT

Read More

India to make drugs for diabetes, obesity under PLI by 2026, says report

The Indian government plans to introduce a production-linked incentive (PLI) program in 2026 to boost domestic manufacturing of GLP-1 drugs, used for treating diabetes and obesity. The anti-obesity medication market is projected to reach $100 billion by 2030, as per Goldman Sachs Research. Major Indian pharmaceutical companies like Sun Pharmaceutical Industries Ltd., Cipla Ltd., and Dr. Reddy’s Laboratories Ltd. are developing weight-loss formulations and generic drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZEV8iPJ
via IFTTT

Read More

Why self-medicating without consulting a dermatologist is a bad idea

The pursuit of flawless skin through unguided skincare practices, influenced by social media and beauty trends, can result in adverse reactions. Seeking professional advice before experimenting with potent products is crucial to prevent skin damage and maintain skin health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FG4xpLY
via IFTTT

Read More

Risk-based audits of drug units to begin from July 1

The revised Schedule M, which is considered more stringent than the World Health Organization's (WHO) good manufacturing practices (GMP) in certain areas, was notified on December 28, 2023. Companies with turnover of over ₹250 crore will have to comply with the upgraded version of Schedule M, starting July 1, and the remaining others, which are largely micro, small, and medium enterprises (MSMEs), have been given a year's time to comply. Inspections on those firms will begin from January 1, 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/erNkOYW
via IFTTT

Read More

WHO warns alarming levels of physical inactivity among Indians, says women more physically inactive than men

A study in The Lancet Global Health highlights that nearly 50% of Indian adults are physically inactive, posing severe health risks. The study shows a significant rise in inactivity from 2000 to 2022, with women being more affected than men. City doctors attribute this to sedentary office work and poor diets. The lack of physical activity increases the risk of cardiovascular diseases, cancers, and psychological issues. Experts stress the need for regular exercise and healthier lifestyles to address this growing concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OerSyTk
via IFTTT

Read More

India pharma units fare better in US checks in 2023

The drug regulator United States Food and Drug Administration (USFDA) has classified 13%, or 19 out of 145 inspections it carried out against Indian facilities, as Official Action Indication (OAI) in 2023, which is lower than the global average of 15% OAIs, according to a report by Indian Pharmaceutical Alliance and McKinsey & Company said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/12gmDGe
via IFTTT

Read More

Norms soon on disposing of expired medicines

The document is in the final stages of completion. It will include procedures to be followed for disposal, collection, storage and transportation of expired and unused drugs. Improper disposal of medications that have crossed the expiry date mentioned on the label or not used by the individual for whom they were prescribed and purchased may be hazardous to public health, animal health and environment, officials said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Cuqz56X
via IFTTT

Read More

Dr Reddy's to buy nicotine replacement brands from UK-based Haleon for $632 million

The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uspxoX4
via IFTTT

Read More

Diabetes management made easier: Your guide to a healthier lifestyle

Proactively collaborating with healthcare professionals for personalized strategies enhances diabetes management, leading to improved overall well-being and better health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QmS8bNl
via IFTTT

Read More

World's first epilepsy device fitted in 13 year old UK boy's skull; Here's how the device works

Oran Knowlson, a 13-year-old from England with severe epilepsy, has become the first person to trial a new device implanted in his skull to control seizures. The groundbreaking surgery, which took place at Great Ormond Street Hospital in London, has reduced Oran's seizures by 80%. The device, a Picostim neurotransmitter, aims to disrupt abnormal brain signals causing epilepsy. Oran's improved quality of life following the surgery has brought hope to others with treatment-resistant epilepsy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XLSewzD
via IFTTT

Read More

US lawmakers questions FDAs drug inspection programme in India and China

Three top American lawmakers have raised concerns about the FDA's foreign drug inspection program in India and China. In a letter to FDA Commissioner Robert Califf, they highlighted inconsistencies in inspection outcomes from January 2014 to April 2024. Some inspectors reported no compliance issues in numerous inspections, while others found issues in almost every inspection. The lawmakers, Cathy McMorris Rodgers, Brett Guthrie, and Morgan Griffith, pointed out these discrepancies and called for an investigation into the skill and thoroughness of FDA inspectors to ensure rigorous and consistent inspections.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kzTDcsP
via IFTTT

Read More